Ernexa Therapeutics Inc.
ERNA
$4.27
-$0.03-0.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 1.00K | 488.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 1.00K | 488.00K |
| Cost of Revenue | -- | -- | -- | 0.00 | -60.00K |
| Gross Profit | -- | -- | -- | 1.00K | 548.00K |
| SG&A Expenses | 5.32M | 5.37M | 5.16M | 5.28M | 7.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.74M | 10.13M | 9.32M | 9.92M | 12.25M |
| Operating Income | -11.74M | -10.13M | -9.32M | -9.92M | -11.76M |
| Income Before Tax | -12.35M | -11.48M | -14.13M | -18.31M | -43.67M |
| Income Tax Expenses | -96.00K | -93.00K | -45.00K | 28.00K | 34.00K |
| Earnings from Continuing Operations | -12.26 | -11.39 | -14.08 | -18.34 | -43.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.26M | -11.39M | -14.08M | -18.34M | -43.70M |
| EBIT | -11.74M | -10.13M | -9.32M | -9.92M | -11.76M |
| EBITDA | -11.69M | -10.08M | -9.25M | -9.85M | -11.67M |
| EPS Basic | -18.69 | -30.50 | -81.30 | -133.12 | -1.97K |
| Normalized Basic EPS | -11.66 | -18.99 | -52.29 | -90.61 | -334.79 |
| EPS Diluted | -18.69 | -30.50 | -81.30 | -133.12 | -1.97K |
| Normalized Diluted EPS | -11.66 | -18.99 | -52.29 | -90.61 | -334.79 |
| Average Basic Shares Outstanding | 2.63M | 1.66M | 1.01M | 780.30K | 465.70K |
| Average Diluted Shares Outstanding | 2.63M | 1.66M | 1.01M | 780.30K | 465.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | 0.00% |